Therapeutics

From day one, our goal has been to leverage our unique proprietary technologies and know-how to build a company that would bring safer, more cost-effective and more convenient therapeutic products to under served patient populations in both existing and emerging markets. Below you will find the latest updates for our leading indications including clinical trial results, FDA & EMA designations.

  • PBI-4050 KOL Event: Alstrom & NASH Sept 7 2018

    PBI-4050 KOL Event: Alstrom & NASH Sept 7 2018

    Prometic is hosting a key opinion leader luncheon to discuss our lead candidate PBI-4050 for Alstrom Syndrome and a promising therapeutic candidate for NASH

    Read PDF
  • Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome

    Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome

    Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).

    Read Article
  • Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology

    Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology

    n the ongoing Phase 2 clinical trial in patients with Alström syndrome, PBI-4050 was shown to significantly reduce liver and cardiac fibrosis.

    Read Article
  • Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050

    Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050

    In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF).

    Read Article
  • Find out more about PBI-4050

    Learn More
  • Pivotal data for Prometic’s intravenous Plasminogen replacement therapy to be presented at American Society for Hematology

    Pivotal data for Prometic’s intravenous Plasminogen replacement therapy to be presented at American Society for Hematology

    Prometic today announced that it will have two presentations at the 59th American Society of Hematology (ASH) Annual Meeting being held Dec. 9-12, 2017 in Atlanta.

    Read Article
  • Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer phase 2 clinical trial

    Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer phase 2 clinical trial

    The Phase 2 clinical trial is a prospective, dose escalation study of the safety, feasibility and initial efficacy of subcutaneous plasminogen for the treatment of DFU in 20 adult subjects.

    Read Article
  • Prometic receives priority review status from Health Canada for Plasminogen (Ryplazim™)

    Prometic receives priority review status from Health Canada for Plasminogen (Ryplazim™)

    Read Article
  • Find out more about Plasminogen

    Learn More
  • loading
    Loading More...